{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:28:04Z","timestamp":1761920884873,"version":"3.41.2"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T00:00:00Z","timestamp":1620000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"DOI":"10.3389\/fneur.2021.662353","type":"journal-article","created":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T04:41:22Z","timestamp":1620016882000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Editorial: Epidemiology of Atypical Demyelinating Diseases"],"prefix":"10.3389","volume":"12","author":[{"given":"Dalia","family":"Rotstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su-Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yael","family":"Hacohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Levy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,5,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology."},{"key":"B2","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1001\/jamaneurol.2017.4601","article-title":"Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"75","author":"Hacohen","year":"2018","journal-title":"JAMA Neurol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1001\/jamaneurol.2020.2743","article-title":"Application of 2015. seronegative neuromyelitis optica spectrum disorder diagnostic criteria for patients with myelin oligodendrocyte glycoprotein IgG-Associated disorders","volume":"77","author":"Kunchok","year":"2020","journal-title":"JAMA Neurol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e468","DOI":"10.1212\/NXI.0000000000000468","article-title":"Mortality in neuromyelitis optica is strongly associated with African ancestry","volume":"5","author":"Mealy","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e2089","DOI":"10.1212\/WNL.0000000000006574","article-title":"Racial differences in neuromyelitis optica spectrum disorder","volume":"91","author":"Kim","year":"2018","journal-title":"Neurology."},{"key":"B6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/ana.25909","article-title":"Clinical features and risk of relapse in children and adults with myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"89","author":"Cobo-Calvo","year":"2021","journal-title":"Ann Neurol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1001\/jamaneurol.2019.2940","article-title":"Serial anti-myelin oligodendrocyte glycoprotein antibody analyses and outcomes in children with demyelinating syndromes","volume":"77","author":"Waters","year":"2020","journal-title":"JAMA Neurol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1093\/brain\/awz054","article-title":"Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders","volume":"142","author":"Palace","year":"2019","journal-title":"Brain."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1093\/brain\/awaa255","article-title":"Vascular disease and multiple sclerosis: a post-mortem study exploring their relationships","volume":"143","author":"Geraldes","year":"2020","journal-title":"Brain."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1177\/1352458518815596","article-title":"Spinal cord lesions and atrophy in NMOSD with AQP4-IgG and MOG-IgG associated autoimmunity","volume":"25","author":"Chien","year":"2019","journal-title":"Mult Scler."},{"key":"B11","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jneuroim.2016.02.004","article-title":"Lesion length of optic neuritis impacts visual prognosis in neuromyelitis optica","volume":"293","author":"Akaishi","year":"2016","journal-title":"J Neuroimmunol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e708","DOI":"10.1212\/NXI.0000000000000708","article-title":"Serum biomarkers in myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"7","author":"Kim","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B13","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12974-019-1525-1","article-title":"Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease","volume":"16","author":"Cobo-Calvo","year":"2019","journal-title":"J Neuroinflammation."},{"key":"B14","doi-asserted-by":"publisher","first-page":"102251","DOI":"10.1016\/j.msard.2020.102251","article-title":"Treatment of MOG-IgG-associated disorder with rituximab: an international study of 121 patients","volume":"44","author":"Whittam","year":"2020","journal-title":"Mult Scler Relat Disord."},{"key":"B15","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1126\/science.aay3638","article-title":"A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis","volume":"371","author":"Krienke","year":"2021","journal-title":"Science."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e277","DOI":"10.1212\/NXI.0000000000000277","article-title":"Restoring immune tolerance in neuromyelitis optica: Part II","volume":"3","author":"Bar-Or","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.662353\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T04:41:24Z","timestamp":1620016884000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.662353\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,3]]},"references-count":16,"alternative-id":["10.3389\/fneur.2021.662353"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.662353","relation":{},"ISSN":["1664-2295"],"issn-type":[{"type":"electronic","value":"1664-2295"}],"subject":[],"published":{"date-parts":[[2021,5,3]]},"article-number":"662353"}}